A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
- Authors:
- Published online on: April 5, 2018 https://doi.org/10.3892/ol.2018.8444
- Pages: 8703-8710
Abstract
Introduction
Lung cancer is the leading cause of cancer-associated mortality in China and worldwide (1). In 2015, an estimated 733,300 new cases of lung and bronchial cancer were diagnosed, and 610,200 mortalities were estimated to occur in China as a result of this disease (2). Approximately 80% of lung cancer cases involve non-small-cell lung cancer (NSCLC), which has an overall 5-year relative survival rate of <20%, while an exceptionally high mortality rate is reported for patients with advanced NSCLC (3). During the past decades, genomic medicine has increased our understanding of the molecular characterization of cancer. The treatment strategy for advanced NSCLC has changed from the traditional chemotherapy based on pathologic histology to individualized precision treatment based on the oncogenic drivers (3).
Fusions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene along with other ALK gene rearrangements (referred to as ALK-positive) are detected in 3–7% of NSCLC patients. The EML4-ALK translocation was first identified as an oncogene in a small proportion of patients with NSCLC in 2007, and the chemical inhibition of the EML4-ALK fusion protein demonstrated an anti-tumor effect in vivo and in vitro (4,5).
Crizotinib, a multitargeted tyrosine kinase inhibitor of ALK, MET and ROS1, had been originally developed as an inhibitor of the c-MET growth factor receptor tyrosine kinase (6). In 2011, this drug received accelerated approval under the US Food and Drug Administration (FDA) for treating ALK-positive advanced NSCLC patients based on two single-arm clinical trials, namely PROFILE 1001 and PROFILE 1005 (7,8). Subsequently, crizotinib was evaluated in several randomized clinical trials, demonstrating superior response rate (RR) and progression-free survival (PFS) to chemotherapy, in first- and second-line settings (PROFILE 1007 and PROFILE 1014) (9,10). Recently, another first-line randomized trial (PROFILE 1029) with the same design as PROFILE 1014, confirmed that crizotinib was able to improve the objective RR (ORR) and PFS compared with chemotherapy in the Asian populations (11). To date, crizotinib has been approved by the China FDA for the treatment of advanced or metastasis ALK-translocated NSCLC.
To date, published real-world data on the treatment patterns and outcomes of patients with ALK-positive advanced NSCLC in China are limited. Therefore, the present study aimed to characterize the treatment patterns and to estimate the survival of patients in China with locally advanced or metastatic ALK-positive NSCLC. Exploratory experimentation was used to investigate independent prognostic factors associated with survival in this cohort.
Patients and methods
Ethical approval
All procedures performed in the present study involving human participants were in accordance with the ethical standards of the Research Ethics Committee of Zhejiang Cancer Hospital and with the 2013 Declaration of Helsinki. Since this is a retrospective study, patient informed consent was not required.
Patient enrollment
A total of 83 patients with locally advanced or metastatic ALK-positive NSCLC who were treated at the Zhejiang Cancer Hospital (Hangzhou, China) during the period of July 2010 and April 2017 were included in the present study. Exclusion criteria in this study were as follows: (i) patients with other types of malignancy; (ii) patients who did not pursue treatment after diagnosis, and (iii) patients who were lost to follow up. Patient data were collected including the following variables: Gender, age, histological subtype, stage (8th edition of the American Joint Committee on Cancer Tumor-Node-Metastasis staging system) (12), smoking history, metastatic sites, therapeutic regimens, efficacy of treatment, date of progression, site of progression and date of mortality. ALK rearrangements were detected by the Ventana ALK (D5F3) CDx immunohistochemical assay (Ventana Medical Systems, Inc., Tucson, AZ, USA), according to the manufacturer's protocol (13).
Follow-up procedures
Patients receiving chemotherapy were evaluated for response every two treatment cycles during treatment and then every 2 months after treatment. Among the 50 patients receiving first-line chemotherapy, 27 were treated with pemetrexed (administered at a dose of 500 mg/m2 by intravenous infusion on day 1 and every subsequent 21 days, for 4–6 cycles) in addition to cisplatin (administered at a dose of 25 mg/m2 by intravenous infusion daily on days 1 to 3 and every subsequent 21 days, for 4–6 cycles)/carboplatin [administered at a dose of AUC (area under the curve)=5 by intravenous infusion on day 1, and every subsequent 21 days, for 4–6 cycles], 11 were treated with docetaxel (administered at a dose of 75 mg/m2 by intravenous infusion on day 1, and every subsequent 21 days for 4–6 cycles) in addition to cisplatin/carboplatin, and 12 were treated with gemcitabine (administered at a dose of 1,000 mg/m2 on day 1 and day 8, and every subsequent 21 days for 4–6 cycles) in addition to cisplatin/carboplatin.
Patients receiving crizotinib were evaluated for response 1 month after the initial treatment and then every 2 months during treatment. Brain or bone lesions that were detected at the time of screening were evaluated in all subsequent tumor assessments. For patients without brain or bone metastasis at baseline assessment, brain and bone scanning was repeated every 6 months or when related symptoms appeared.
The response evaluation of the tumor to therapy was based on computed tomography or magnetic resonance imaging scanning. The short-term efficacy was defined based on version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (14). The long-term efficacy was evaluated according to the PFS and overall survival (OS). PFS1 was defined as the time from the initiation of treatment to the radiological evidence of first progressive disease (PD). PFS2 was defined as the time between the first and the second RECIST-defined PD. OS was calculated from the initiation of treatment to mortality.
Statistical analysis
Statistical analysis was performed using SPSS version 22.0 software (IBM Corp., Armonk, NY, USA). Statistically significant differences was indicated by P<0.05. χ2-test was applied to examine the association between the efficacy and therapeutic regimens. Survival rates were analyzed using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analysis were performed with the Cox proportional hazard model.
Results
Patient characteristics
A total of 83 patients, treated at the Zhejiang Cancer Hospital between July 2010 and April 2017, were enrolled into the present study. The patient characteristics are listed in Table I. The median age at diagnosis was 50 years (ranging between 23 and 79 years), and more than half of the patients were female (56.6%). The most common histological type was adenocarcinoma (92.8%), and 61.4% of the patients were not smokers. In total, 7 (8.4%) patients were diagnosed with stage IIIB disease and 76 (91.6%) patients with stage IV disease. Among them, 34.9% displayed intrapulmonary metastasis, 10.8% had intracranial metastasis, 20.5% had liver metastasis, 34.9% had bone metastasis, and 32.5% presented pleural effusion. Until the last follow up (June 7, 2017), the median follow-up time was 23.6 months (range, 1.2–66.9 months).
Efficacy and survival of initial therapy
The treatment efficacy of the 83 patients was listed in Table II. Among these patients, 33 (39.8%) received crizotinib and 50 (60.2%) received chemotherapy as the initial therapy. Among the 50 patients receiving first-line chemotherapy, 27 were treated with pemetrexed (administered at a dose of 500 mg/m2 by intravenous infusion on day 1, every 21 days) plus cisplatin (administered at a dose of 25 mg/m2 by intravenous infusion daily on days 1 to 3, every 21 days)/carboplatin (administered at a dose of AUC=5 by intravenous infusion on day 1, every 21 days), 11 were treated with docetaxel (administered at a dose of 75 mg/m2 by intravenous infusion on day 1, every 21 days) plus cisplatin/carboplatin, and 12 were treated with gemcitabine (administered at a dose of 1,000 mg/m2 on day 1 and day 8, every 21 days) plus cisplatin/carboplatin. The ORR was significantly higher in patients receiving crizotinib as compared with those treated with chemotherapy (72.7 vs. 38%, respectively; P=0.003).
Until the last follow-up, 67 patients had disease progression. The median PFS1 was 18.5 months [95% confidence interval (CI), 12.4–24.6 months] among patients in the crizotinib group, as compared with 4.9 months (95% CI, 2.8–7.1 months) among patients in the chemotherapy group [hazard ratio (HR) for progression or mortality in crizotinib group, 0.345; 95% CI, 0.201–0.594; P<0.001; Fig. 1A]. Intracranial lesion progression or development of new intracranial lesions was reported in significantly more patients in the crizotinib group (n=10; 50%) as compared with those in the chemotherapy group (n=4; 8.5%; P<0.001; data not shown). Intrapulmonary lesion progression was reported in a significantly higher number of patients in the chemotherapy group (n=17; 36.2%) as compared with that in the crizotinib group (n=2; 10.0%; P<0.05). There was no difference between the pleural lesion progression in the crizotinib group (n=4; 20%) and the chemotherapy group (n=13; 27.7%; P=0.760). In addition, there was no significant difference in the OS between patients who received crizotinib and those who received chemotherapy in the first-line setting (P=0.802; Fig. 1B).
Survival of patients following the first progression
Table III presents the treatment patterns of the 83 patients. Of the 50 patients receiving chemotherapy as the initial therapy, 47 experienced disease progression until the final follow-up. Among them, crizotinib was administered as second-line therapy in 22 (46.8%) cases, the chemotherapy regimen was changed in 19 (40.4%) cases, and 6 (12.8%) patients did not receive any other therapy beyond the first progression. The median PFS2 was 16.4 months (95% CI, 6.4–26.4 months) among patients in the crizotinib group, as compared with 3.5 months (95% CI, 1.0–6.1 months) among patients in the chemotherapy group (P<0.001) and 3.2 months (95% CI, 1.0–5.3 months) among patients in the first-line treatment only group (P=0.001; Fig. 2).
Of the 33 patients receiving crizotinib as the initial therapy, 20 experienced disease progression until the final follow-up. Among them, treatment was changed to chemotherapy in 6 (30.0%) cases, crizotinib treatment was continued along with local radiotherapy in 13 (65%) cases and 1 (5%) case did not receive any other therapy beyond the first progression. Of the 13 patients continued on crizotinib and receiving local radiotherapy, the median follow-up time beyond the first progression was 42.7 weeks (95% CI, 0.6–122.1 weeks). Until the last follow up, the median PFS2 of these patients had not been reached.
Survival of crizotinib patients
At the last follow up, 71 (85.5%) patients had received crizotinib, and 12 (14.5%) patients were crizotinib naive. Of the 71 patients receiving crizotinib, 33 (46.5%) received this therapy in the first-line setting, 22 (31%) received this in the second-line setting, and 16 (22.5%) received crizotinib in the third-line or further setting. There was no significant difference in OS among these three groups (P=0.577; Fig. 3A). However, patients receiving crizotinib had an improved OS as compared with patients that were crizotinib-naive (HR, 0.279; 95% CI, 0.107–0.727; P<0.05; Fig. 3B).
Univariate analysis for OS
Factors that were analyzed by univariate analysis are listed in Table IV. The gender (P=0.028), smoking history (P=0.011), liver invasion at diagnosis (P=0.023), bone invasion at diagnosis (P=0.01) and the use of crizotinib (P=0.018) were significantly associated with the OS. However, crizotinib used in the first-line setting, in the second-line setting or after the second-line setting was not associated with the OS.
Multivariate analysis
The Cox multivariate analysis identified the following independent negative prognostic factors for OS: Smoking history (HR=4.565), liver invasion at diagnosis (HR=4.294) and bone invasion at diagnosis (HR=2.587). In addition, the use of crizotinib (HR=0.319) was identified as positive prognostic factor for OS (Table V).
The 2 year OS rate for patients who had never smoked was 85%, with a rate of 54% for those who were former or current smokers. Patients with liver invasion at diagnosis had a 2-year OS rate of 81%, as compared with the rate of 49% for patients with non-liver invasion. Furthermore, patients with bone invasion at diagnosis had a 2-year OS rate of 83%, as compared with the rate of 59% for those with non-bone invasion. Patients who received crizotinib had a 2-year OS rate of 80%, as compared with the rate of 42% for those who were crizotinib-naive.
Discussion
Molecular targeted therapy of advanced NSCLC represents the paradigm of personalized treatment of malignancies. Several druggable cancer driver genes have been identified thus far, with epidermal growth factor receptor mutation and ALK gene rearrangements being the most characteristic features of the disease (15). ALK rearrangements occur in 3–7% of patients with NSCLC. Although the proportion of ALK-positive patients is relatively low, the number of ALK-positive patients in China is anticipated to be significant due to the large population base and the high incidence of lung cancer. In China, crizotinib has been approved as a first-line monotherapy for advanced or metastatic patients with ALK-positive NSCLC, and as a second-line monotherapy for those who have received prior chemotherapy. However, to date, limited data have been published on the treatment patterns and outcomes of Chinese ALK-positive NSCLC patients.
In the current real-world study, the characteristics of patients were consistent with those reported in previous studies (16,17). More specifically, ALK rearrangement occurred in relatively young patients, >50% of the patients had no history of smoking and almost all patients were diagnosed with adenocarcinoma. In addition, bone and pleural metastasis at diagnosis was reported in approximately one third of the patients, while brain metastasis at diagnosis was observed in ~10% of patients in the present study. It has previously been reported that ALK-positive NSCLC does not appear to be associated with an increased risk of brain metastases at the first diagnosis (16). The incidence of intracranial invasion in newly diagnosed ALK-positive advanced NSCLC patients has been demonstrated to range from 20–30%, which was similar to that of non-ALK-positive disease (18,19). In the univariate analysis conducted in the current study, smoking history was associated with worse OS. A study that provided a 50-year perspective on the evolution of smoking-associated risks in the United States has demonstrated that, among patients with lung cancer, smokers had an increased mortality rate as compared with nonsmokers (20). Another study revealed that the rate of mortality from any cause among current smokers was ~3 times that reported among individuals who had never smoked (21).
Although two randomized stage III clinical trials (10,11) have demonstrated a higher ORR and longer PFS of first-line crizotinib treatment when compared with that in patients receiving chemotherapy, more than half (60.2%) of the 83 patients selected chemotherapy as the initial therapy in the present study. The main reason for this phenomenon is the fact that crizotinib is not currently included in the medical insurance catalogue in China, leading to certain patients unable to afford such an expensive drug at the beginning of treatment. In the current study, the ORR and PFS1 were also significantly improved in the crizotinib group as compared with the chemotherapy group. Notably, the PFS of patients receiving crizotinib as the initial therapy (median PFS, 18.5 months) was longer compared with the PFS results of the PROFILE 1014 (median PFS, 10.9 months) and PROFILE 1029 (median PFS, 11.1 months) trials. A similar PFS result (median PFS, 17.6 months) was reported in another real-world study from a single center in China (22). In the previous clinical trials (10,11), brain and bone scanning was repeated every 12 weeks to monitor for new lesions in the follow-up schedule. By contrast, in the present study, brain and bone scanning was repeated every 6 months or when associated symptoms appeared in patients without brain or bone metastasis at the baseline assessment. This may have resulted in an artificially prolonged PFS in the crizotinib group since intracranial progression occurred in half of the patients with disease progression. In addition, according to previous studies, different EML4-ALK variants may exhibit a different response to crizotinib, of which the EML4-ALK variant 1 had significantly longer PFS in comparison with other EML4-ALK variants (median, 31.1 vs. 5.7 months, respectively; P=0.003) (23,24). This may be one of the reasons for the PFS difference between the current study and previous clinical trials; however, further investigation is required to test this hypothesis.
The estimation of OS in patients treated with crizotinib has not yet been fully documented. In the present analysis, there was no significant difference in OS between patients receiving crizotinib and those receiving chemotherapy in the first-line setting. Similar results were observed in the PROFILE 1014 and PROFILE 1029 trials comparing crizotinib to pemetrexed-plus-platinum as the first-line therapy, possibly due to a cross-over in the chemotherapy arm. Indeed, in the current study, 38 (76.0%) of the 50 patients receiving chemotherapy as the initial therapy were administered crizotinib as subsequent therapy. In addition, there were no statistically significant difference in the OS among patients using crizotinib in the first-line, second-line and third-line or further setting in the present study. However, patients receiving crizotinib exhibited improved OS in comparison with patients who were crizotinib-naive. A retrospective analysis comparing 30 crizotinib-treated ALK-positive NSCLC patients with 23 crizotinib-naive patients reported similar results, with the patients in the crizotinib group exhibiting a longer OS (25). The current Cox multivariate analysis also identified the use of crizotinib, but not the line of usage as an independent prognostic factor for OS.
Despite a great response rate, the vast majority of patients with ALK-rearranged NSCLC inevitably experienced acquired resistance in ~1 year. The central nervous system (CNS) has been reported to be a frequent site of acquired resistance to crizotinib in patients with ALK-positive NSCLC (26–28). In the present study, cerebral progression occurred in more patients in the crizotinib group (n=10; 50%) in comparison with those in the chemotherapy group (n=4; 8.5%). Consistently, the prevalence of CNS metastases in crizotinib-refractory patients was approximately twice as high as that of crizotinib-naive patients in previous studies (29,30). This phenomenon can be largely attributed to the following two reasons: Firstly, crizotinib is a substrate of P-glycoprotein, a membranous transporter overexpressed in the hematoencephalic barrier and responsible for the efflux of the drug. Low cerebrospinal fluid-to-serum ratios have been reported for crizotinib in the range between 0.06 and 0.26% (31,32). Furthermore, crizotinib extended the patient survival, which to a certain extent may be contributed to the higher incidence of CNS metastases as compared with chemotherapy.
In the current study, of the patients receiving crizotinib as the initial therapy, 20 experienced disease progression, 13 (65%) were continued on crizotinib and received local radiotherapy beyond the first progression. In these 13 patients, the median follow-up time subsequent to the first progression was 42.7 weeks. Until the last follow-up, the median PFS2 of these patients had not been reached. Prior to second-generation ALK inhibitors being available, treatment with crizotinib was often continued beyond disease progression in clinical practice and trials. For instance, in the phase 3 randomized trial PROFILE 1014 (10), 73% of patients with previously untreated ALK-positive NSCLC were continued on crizotinib beyond disease progression for a median of 3.1 months. A retrospective analysis of patients in the PROFILE 1001 and PROFILE 1005 studies revealed that 62% (120/194) of the patients continued crizotinib therapy after the RECIST-defined PD. Among the 120 patients, 51% had brain metastases as the sole site of PD, and the results revealed that this treatment strategy may improve survival (33). The therapeutic strategy of continuing crizotinib beyond disease progression has also been supported by several retrospective studies, in which continued ALK inhibition with crizotinib was associated with clinical benefits and prolonged OS (34–36). In a recently published physician survey and retrospective chart review study in the US, the majority of physicians (75%) would add local therapy and resume crizotinib when a new symptomatic isolated lesion was detected in ALK-positve NSCLC treated with crizotinib (37).
Mechanisms of acquired resistance to crizotinib commonly include secondary mutations within the ALK tyrosine kinase domain. Therefore, during the last decade more potent and structurally different inhibitors have been developed (38,39). Since the development of second-generation ALK-inhibitors, which were demonstrated to be effective in crizotinib-resistant patients, are not available in China, the continuation of crizotinib plus local treatment may be a feasible option to maximize the overall clinical benefits for patients with local-site progression post crizotinib.
In conclusion, the present real-world study demonstrated that the use of crizotinib improved the long-term survival of advanced NSCLC patients with ALK rearrangement as compared with crizotinib-naive patients. There was no difference in the survival outcome between patients with initial use of crizotinib and those with subsequent use of crizotinib beyond first-line therapy. CNS was a frequent site of acquired resistance to crizotinib, and the continuation of crizotinib plus local treatment may improve the survival. However, head-to-head trials comparing second- or third-generation ALK inhibitors with the continuation of crizotinib beyond progression are necessary to provide the optimum treatment strategy.
Acknowledgements
Not applicable.
Funding
The present study was supported by the Wu Jie Ping Medical Foundation (grant no. wjpzlz-160830-01).
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
YJ contributed to the acquisition of data and prepared the manuscript. YC performed the statistical analysis. XY revised the manuscript critically for important intellectual content. XS and XY designed the study.
Ethics approval and consent to participate
All procedures performed in the present study involving human participants were in accordance with the ethical standards of the Research Ethics Committee of Zhejiang Cancer Hospital (Zhejiang, China) and with the 2013 Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
Boolell V, Alamgeer M, Watkins DN and Ganju V: The evolution of therapies in non-small cell lung cancer. Cancers. 7:1815–1846. 2015. View Article : Google Scholar : PubMed/NCBI | |
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI | |
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cacner. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67:4408–4417. 2007. View Article : Google Scholar : PubMed/NCBI | |
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI | |
Crino L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge DR, Hirsh V, Mok T, Solomon BJ, Park K, et al: Initial phase II results with crizotinib in advanced ALK-posivie non-small cell lung cancer (NSCLC): PROFILE 1005. ASCO Meet Abstr. 29 15 Suppl:75142011. | |
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cacner. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI | |
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lu S, Mok T, Lu Y, Zhou J, Shi Y and Sriuranpong V: Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 34 15 Suppl:90582016. | |
Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H and Goldstraw P: International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions: The IASLC lung cancer staging project: The new database to inform the eighth edition of the TNM classfication of lung cancer. J Thorac Oncol. 9:1618–1624. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR and Hirsch FR: An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 9:631–638. 2014. View Article : Google Scholar : PubMed/NCBI | |
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI | |
Melosky B: Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol. 7:382017. View Article : Google Scholar : PubMed/NCBI | |
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, et al: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhang YG, Jin ML, Li L, Zhao HY, Zeng X, Jiang L, Wei P, Diao XL, Li X, Cao Q and Tian XX: Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. PLoS One. 8:e648212013. View Article : Google Scholar : PubMed/NCBI | |
Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, et al: Oncogene status predicts patterns of metastatic spread in treatment-naïve non-small cell lung cancer. Cancer. 118:4502–4511. 2012. View Article : Google Scholar : PubMed/NCBI | |
Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, et al: CH5424802(RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1–2 study. Lancet Oncol. 14:590–598. 2013. View Article : Google Scholar : PubMed/NCBI | |
Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, Hartge P and Gapstur SM: 50-year trends in smoking-related mortality in the United States. N Engl J Med. 368:351–364. 2013. View Article : Google Scholar : PubMed/NCBI | |
Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T and Peto R: 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 368:341–350. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chen G, Chen X, Zhang Y, Yan F, Fang W, Yang Y, Hong S, Miao S, Wu M, Huang X, et al: A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. Cancer Med. 6:953–961. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T and Yatabe Y: Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 34:3383–3389. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cha YJ, Kim HR and Shim HS: Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. J Transl Med. 14:2962016. View Article : Google Scholar : PubMed/NCBI | |
Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et al: Effect of crizotinib on overall survival in pateints with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI | |
Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 33:1881–1888. 2015. View Article : Google Scholar : PubMed/NCBI | |
Camidge DR: Taking aim at ALK across the blood-brain barrier. J Thorac Oncol. 8:389–390. 2013. View Article : Google Scholar : PubMed/NCBI | |
Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, Ludovini V, Crinò L and Gori S: CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 10:e26–27. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, et al: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol. 34:661–668. 2016. View Article : Google Scholar : PubMed/NCBI | |
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, et al: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol. 17:234–242. 2016. View Article : Google Scholar : PubMed/NCBI | |
Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W and Wilner KD: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 29:e443–445. 2011. View Article : Google Scholar : PubMed/NCBI | |
Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, Ludovini V, Crinò L and Gori S: CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 10:e26–27. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW and Riely GJ: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol. 25:415–422. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hong X, Chen Q, Ding L, Liang Y, Zhou N, Fang W, Chen X and Wu H: Clinical benefit of continuing crizotinib therapy after initial disease progression in Chiniese pateints with advanced ALK-rearranged non-small-cell lung cancer. Oncotarget. 8:41631–41640. 2017. View Article : Google Scholar : PubMed/NCBI | |
Takeda M, Okamoto I and Nakagawa K: Clinical impact of continued crizotinib administration after isolated central nervous system progresssion in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol. 8:654–657. 2013. View Article : Google Scholar : PubMed/NCBI | |
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC and Camidge DR: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cacner. J Thorac Oncol. 7:1807–1814. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR and Guérin A: Monitoring for and characterizing crizotinib progression: A chart review of ALK-positive non-small cell lung cancer pateints. Adv Ther. 34:1673–1685. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wu JJ, Savooji J and Liu DL: Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. 9:192016. View Article : Google Scholar : PubMed/NCBI | |
Su S and Wu YL: Clinical trials of tyrosine kinase inhibitors for lung cancer in China: A review. J Hematol Oncol. 10:1472017. View Article : Google Scholar : PubMed/NCBI |